Global Benign Prostatic Hyperplasia (BPH) Drugs Market Research Report 2020
- BMR3856526
- 150 Pages
- May 2020
- Healthcare
This report focuses on Benign Prostatic Hyperplasia (BPH) Drugs volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Benign Prostatic Hyperplasia (BPH) Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, APAC, South America and MEA.
Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt and will significantly affect the Benign Prostatic Hyperplasia (BPH) Drugs market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Benign Prostatic Hyperplasia (BPH) Drugs industry.
By Company
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck
Segment by Type
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
Segment by Application
Hospitals
Drugstores
Others
By Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
South America
Brazil
Colombia
Argentina
Middle East & Africa
Middle East
Africa
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Drugs 1
1.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type 1
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate Comparison by Type (2020-2026) 2
1.2.2 Alpha-Blocker 3
1.2.3 Phosphodiesterase Type-5 Inhibitors 4
1.2.4 Others 5
1.3 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application 6
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Comparison by Application (2020-2026) 6
1.3.2 Hospitals 7
1.3.3 Drugstores 8
1.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Estimates and Forecasts 9
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2015-2026 9
1.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2015-2026 10
1.4.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region: 2020 Versus 2026 11
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth 12
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections 12
1.5.2 Covid-19 Impact: Commodity Prices Indices 19
1.5.3 Covid-19 Impact: Global Major Government Policy 24
2 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET COMPETITION BY MANUFACTURERS 29
2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2019-2020) 29
2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturers (2019-2020) 31
2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Manufacturers (2019-2020) 33
2.4 Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Headquarters, Established Date and Products Types 34
2.5 Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Situation and Trends 35
2.5.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Rate 35
2.5.2 The Global 3 and 5 Largest Benign Prostatic Hyperplasia (BPH) Drugs Players Market Share by Revenue 36
2.5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 37
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 37
3 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS RETROSPECTIVE MARKET SCENARIO BY REGION 40
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario in Sales by Region: 2015-2020 40
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020 42
3.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country 43
3.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country 43
3.3.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country 44
3.3.3 United States 45
3.3.4 Canada 46
3.3.5 Mexico 47
3.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country 48
3.4.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country 48
3.4.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country 49
3.4.3 Germany 51
3.4.4 France 52
3.4.5 U.K. 53
3.4.6 Italy 54
3.4.7 Russia 55
3.5 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Region 56
3.5.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region 56
3.5.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region 57
3.5.3 China 59
3.5.4 Japan 60
3.5.5 South Korea 61
3.5.6 India 62
3.5.7 Australia 63
3.5.8 Southeast Asia 64
3.5.9 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country 65
3.5.10 South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country 66
3.5.11 Brazil 67
3.5.12 Colombia 68
3.5.13 Argentina 69
3.6 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country 70
3.6.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country 70
3.6.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country 71
3.6.3 Middle East 72
3.6.4 Africa 73
4 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS HISTORIC MARKET ANALYSIS BY TYPE 75
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020) 75
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2015-2020) 77
4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2015-2020) 78
5 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS HISTORIC MARKET ANALYSIS BY APPLICATION 79
6 ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS INDUSTRY KEY MANUFACTURERS 81
6.1 Eli Lilly 81
6.1.1 Company Profile 81
6.1.2 Product Information 82
6.1.3 Sales, Price, Revenue and Gross Margin 82
6.2 GlaxoSmithKline 83
6.2.1 Company Profile 83
6.2.2 Product Information 84
6.2.3 Sales, Price, Revenue and Gross Margin 84
6.3 Astellas Pharma 85
6.3.1 Company Profile 85
6.3.2 Product Information 86
6.3.3 Sales, Price, Revenue and Gross Margin 86
6.4 Sanofi 87
6.4.1 Company Profile 87
6.4.2 Product Information 88
6.4.3 Sales, Price, Revenue and Gross Margin 88
6.5 Pfizer 89
6.5.1 Company Profile 89
6.5.2 Product Information 90
6.5.3 Sales, Price, Revenue and Gross Margin 90
6.6 Abbott 91
6.6.1 Company Profile 91
6.6.2 Product Information 92
6.6.3 Sales, Price, Revenue and Gross Margin 92
6.7 Allergan 93
6.7.1 Company Profile 93
6.7.2 Product Information 94
6.7.3 Sales, Price, Revenue and Gross Margin 94
6.8 TEVA 95
6.8.1 Company Profile 95
6.8.2 Product Information 96
6.8.3 Sales, Price, Revenue and Gross Margin 96
6.9 Mylan 96
6.9.1 Company Profile 96
6.9.2 Product Information 98
6.9.3 Sales, Price, Revenue and Gross Margin 98
6.10 Novartis 98
6.10.1 Company Profile 98
6.10.2 Product Information 100
6.10.3 Sales, Price, Revenue and Gross Margin 100
6.11 Merck 101
6.11.1 Company Profile 101
6.11.2 Product Information 102
6.11.3 Sales, Price, Revenue and Gross Margin 102
7 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MANUFACTURING COST ANALYSIS 103
7.1 R&D Cost Analysis 103
7.1.1 Clinical Phase Costs 104
7.1.2 Capitalized Costs 105
7.2 Proportion of Manufacturing Cost Structure 106
7.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs 107
7.4 Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis 108
8 MARKETING CHANNEL, DISTRIBUTORS AND CUSTOMERS 109
8.1 Marketing Channel 109
8.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors List 110
8.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers 113
9 MARKET DYNAMICS 115
9.1 Market Trends 115
9.2 Opportunities and Drivers 116
9.3 Challenges 116
9.4 Porter's Five Forces Analysis 116
10 GLOBAL MARKET FORECAST 118
10.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Projections by Type 118
10.1.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2021-2026) 118
10.1.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2021-2026) 118
10.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Projections by Application 119
10.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Projections by Region 120
10.3.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Drugs by Region (2021-2026) 120
10.3.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Drugs by Region (2021-2026) 120
10.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2021-2026) 121
10.5 Europe Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2021-2026) 122
10.6 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2021-2026) 123
10.7 South America Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2021-2026) 124
10.8 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2021-2026) 125
11 RESEARCH FINDINGS AND CONCLUSION 127
12 METHODOLOGY AND DATA SOURCE 128
12.1 Methodology/Research Approach 128
12.1.1 Research Programs/Design 128
12.1.2 Market Size Estimation 129
12.1.3 Market Breakdown and Data Triangulation 130
12.2 Data Source 131
12.2.1 Secondary Sources 131
12.2.2 Primary Sources 132
12.3 Author List 134
12.4 Disclaimer 134
Table 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Comparison by Application (2020-2026) 6
Table 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region (M Units) & (US$ Million): 2020 VS 2026 11
Table 4. Overview of the World Economic Outlook Projections 14
Table 5. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity) 15
Table 6. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise) 16
Table 7. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise) 17
Table 8. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise) 18
Table 9. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise) 19
Table 10. Covid-19 Impact: Global Major Government Policy 24
Table 11. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Covered in This Study 29
Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) of Key Manufacturers (2019-2020) 30
Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2019-2020) 30
Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Manufacturers (2019-2020) 32
Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2019-2020) 32
Table 16. Global Market Benign Prostatic Hyperplasia (BPH) Drugs Average Price (USD/Unit) of Key Manufacturers (2019-2020) 33
Table 17. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Headquarters and Established Date 34
Table 18. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type 34
Table 19. Global Manufacturers Market Concentration Ratio (CR5 and HHI) 35
Table 20. Global Benign Prostatic Hyperplasia (BPH) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2019) 37
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans 37
Table 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2015-2020) (M Units) 40
Table 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2015-2020) 40
Table 24. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2015-2020) (US$ Million) 42
Table 25. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2015-2020) (M Units) 43
Table 26. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020) 43
Table 27. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2015-2020) (US$ Million) 44
Table 28. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020) 44
Table 29. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2015-2020) (M Units) 48
Table 30. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020) 48
Table 31. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2015-2020) (US$ Million) 49
Table 32. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020) 50
Table 33. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2015-2020) (M Units) 56
Table 34. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2015-2020) 56
Table 35. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2015-2020) (US$ Million) 57
Table 36. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2015-2020) 57
Table 37. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2015-2020) (M Units) 65
Table 38. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020) 65
Table 39. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2015-2020) (US$ Million) 66
Table 40. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020) 66
Table 41. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2015-2020) (M Units) 70
Table 42. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020) 70
Table 43. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2015-2020) (US$ Million) 71
Table 44. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020) 71
Table 45. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2015-2020) 75
Table 46. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020) 75
Table 47. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Type (2015-2020) 77
Table 48. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2015-2020) 77
Table 49. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (USD/Unit) by Type (2015-2020) 78
Table 50. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2015-2020) 79
Table 51. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2015-2020) 79
Table 52. Eli Lilly Company Profile 81
Table 53. Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Eli Lilly 2019-2020 82
Table 54. GlaxoSmithKline Company Profile 83
Table 55. Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of GlaxoSmithKline 2019-2020 84
Table 56. Astellas Pharma Company Profile 85
Table 57. Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Astellas Pharma 2019-2020 86
Table 58. Sanofi Company Profile 87
Table 59. Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Sanofi 2019-2020 88
Table 60. Pfizer Company Profile 89
Table 61. Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Pfizer 2019-2020 90
Table 62. Abbott Company Profile 91
Table 63. Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Abbott 2019-2020 92
Table 64. Allergan Company Profile 93
Table 65. Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Allergan 2019-2020 94
Table 66. TEVA Company Profile 95
Table 67. Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of TEVA 2019-2020 96
Table 68. Mylan Company Profile 96
Table 69. Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Mylan 2019-2020 98
Table 70. Novartis Company Profile 98
Table 71. Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Novartis 2019-2020 100
Table 72. Merck Company Profile 101
Table 73. Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Merck 2019-2020 102
Table 74. Out-of-pocket Preclinical and Clinical Period Cost per Investigational Biopharmaceutical Compound 105
Table 75. Capitalized Preclinical and Clinical Period costs per Investigational Biopharmaceutical Compound 106
Table 76. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List 110
Table 77. Market Key Trends 115
Table 78. Key Opportunities and Drivers: Impact Analysis (2021-2026) 116
Table 79. Key Challenges 116
Table 80. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2021-2026) (M Units) 118
Table 81. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Type (2021-2026) 118
Table 82. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Type (2021-2026) (US$ Million) 118
Table 83. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Type (2021-2026) 119
Table 84. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2021-2026) (M Units) 119
Table 85. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Application (2021-2026) 119
Table 86. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Region (2021-2026) (M Units) 120
Table 87. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Region (2021-2026) 120
Table 88. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Region (2021-2026) (US$ Million) 120
Table 89. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Region (2021-2026) 121
Table 90. Research Programs/Design for This Report 128
Table 91. Key Data Information from Secondary Sources 131
Table 92. Key Data Information from Primary Sources 133
Figure 1. Product Picture of Benign Prostatic Hyperplasia (BPH) Drugs 1
Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type in 2020 2
Figure 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type in 2026 3
Figure 4. Alpha-Blocker Product Picture 4
Figure 5. Phosphodiesterase Type-5 Inhibitors Product Picture 5
Figure 6. Others Product Picture 6
Figure 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application in 2020 7
Figure 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application in 2026 7
Figure 9. Hospitals 8
Figure 10. Drugstores 9
Figure 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size 2015-2026 (US$ Million) 10
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2015-2026 (M Units) 10
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size(US$ Million) by Region: 2020 Versus 2026 11
Figure 14. Commodity Prices-Metals Price Indices 20
Figure 15. Commodity Prices- Precious Metal Price Indices 21
Figure 16. Commodity Prices- Agricultural Raw Material Price Indices 21
Figure 17. Commodity Prices- Food and Beverage Price Indices 22
Figure 18. Commodity Prices- Fertilizer Price Indices 22
Figure 19. Commodity Prices- Energy Price Indices 23
Figure 20. G20+: Economic Policy Responses to COVID-19 24
Figure 21. Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Manufacturers in 2019 31
Figure 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers in 2019 33
Figure 23. Figure Global 3 Largest Benign Prostatic Hyperplasia (BPH) Drugs Players: Market Share by Revenue in Benign Prostatic Hyperplasia (BPH) Drugs in 2019 36
Figure 24. Figure Global 5 Largest Benign Prostatic Hyperplasia (BPH) Drugs Players: Market Share by Revenue in Benign Prostatic Hyperplasia (BPH) Drugs in 2019 36
Figure 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2015-2020) 41
Figure 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region in 2019 41
Figure 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2015-2020) 42
Figure 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region in 2019 43
Figure 29. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2019 44
Figure 30. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2019 45
Figure 31. United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units) 45
Figure 32. United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million) 46
Figure 33. Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units) 46
Figure 34. Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million) 47
Figure 35. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units) 47
Figure 36. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million) 48
Figure 37. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2019 49
Figure 38. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2019 50
Figure 39. Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units) 51
Figure 40. Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million) 51
Figure 41. France Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units) 52
Figure 42. France Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million) 52
Figure 43. U.K. Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units) 53
Figure 44. U.K. Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million) 53
Figure 45. Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units) 54
Figure 46. Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million) 54
Figure 47. Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units) 55
Figure 48. Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million) 55
Figure 49. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region in 2019 57
Figure 50. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region in 2019 58
Figure 51. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units) 59
Figure 52. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million) 59
Figure 53. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units) 60
Figure 54. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million) 60
Figure 55. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units) 61
Figure 56. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million) 61
Figure 57. India Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units) 62
Figure 58. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million) 62
Figure 59. Australia Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units) 63
Figure 60. Australia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million) 63
Figure 61. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units) 64
Figure 62. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million) 64
Figure 63. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2019 65
Figure 64. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2019 67
Figure 65. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units) 67
Figure 66. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million) 68
Figure 67. Colombia Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units) 68
Figure 68. Colombia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million) 69
Figure 69. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units) 69
Figure 70. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million) 70
Figure 71. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2019 71
Figure 72. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2019 72
Figure 73. Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units) 72
Figure 74. Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million) 73
Figure 75. Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units) 73
Figure 76. Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million) 74
Figure 77. Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2015-2020) 76
Figure 78. Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type in 2020 76
Figure 79. Revenue Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2015-2020) 77
Figure 80. Revenue Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type in 2020 78
Figure 81. Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application (2015-2020) 80
Figure 82. Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2019 80
Figure 83. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture of Eli Lilly 82
Figure 84. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture of GlaxoSmithKline 84
Figure 85. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture of Astellas Pharma 86
Figure 86. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture of Sanofi 88
Figure 87. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture of Pfizer 90
Figure 88. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture of Abbott 92
Figure 89. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture of Allergan 94
Figure 90. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture of TEVA 96
Figure 91. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture of Mylan 98
Figure 92. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture of Novartis 100
Figure 93. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture of Merck 102
Figure 94. typical phases from research to the market for a drug candidate 104
Figure 95. Manufacturing Cost Structure of Benign Prostatic Hyperplasia (BPH) Drugs 106
Figure 96. Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs 107
Figure 97. Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis 108
Figure 98. Channels of Distribution 110
Figure 99. Distributors Profiles 112
Figure 100. Proportion of Selected Age Groups of World Population in 2019, by Region 114
Figure 101. Porter's Five Forces Analysis 117
Figure 102. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate Forecast (2021-2026) (M Units) 121
Figure 103. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million) 122
Figure 104. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate Forecast (2021-2026) (M Units) 122
Figure 105. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million) 123
Figure 106. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate Forecast (2021-2026) (M Units) 123
Figure 107. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million) 124
Figure 108. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate Forecast (2021-2026) (M Units) 124
Figure 109. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million) 125
Figure 110. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate Forecast (2021-2026) (M Units) 125
Figure 111. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million) 126
Figure 112. Bottom-up and Top-down Approaches for This Report 130
Figure 113. Data Triangulation 131
Figure 114. Key Executives Interviewed 133
Similar Reports
This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.
The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...
- Publish Date: March 2, 2020
- $0
Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...
- Publish Date: March 10, 2011
- $950
The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...
- Publish Date: July 18, 2011
- $950
